- Home
- TXMD vs UMAC Comparison
TXMD vs UMAC Comparison
Compare TXMD & UMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- UMAC
- Stock Information
- Founded
- TXMD 2008
- UMAC 2019
- Country
- TXMD United States
- UMAC United States
- Employees
- TXMD N/A
- UMAC N/A
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- UMAC
- Sector
- TXMD Health Care
- UMAC
- Exchange
- TXMD Nasdaq
- UMAC Nasdaq
- Market Cap
- TXMD 17.9M
- UMAC 20.4M
- IPO Year
- TXMD N/A
- UMAC 2024
- Fundamental
- Price
- TXMD $1.41
- UMAC $2.62
- Analyst Decision
- TXMD
- UMAC Strong Buy
- Analyst Count
- TXMD 0
- UMAC 1
- Target Price
- TXMD N/A
- UMAC $4.00
- AVG Volume (30 Days)
- TXMD 17.4K
- UMAC 139.7K
- Earning Date
- TXMD 11-12-2024
- UMAC 11-14-2024
- Dividend Yield
- TXMD N/A
- UMAC N/A
- EPS Growth
- TXMD N/A
- UMAC N/A
- EPS
- TXMD N/A
- UMAC N/A
- Revenue
- TXMD $1,596,000.00
- UMAC $3,561,303.00
- Revenue This Year
- TXMD $605.07
- UMAC N/A
- Revenue Next Year
- TXMD $1.11
- UMAC $66.18
- P/E Ratio
- TXMD N/A
- UMAC N/A
- Revenue Growth
- TXMD N/A
- UMAC N/A
- 52 Week Low
- TXMD $1.38
- UMAC $0.98
- 52 Week High
- TXMD $3.07
- UMAC $5.54
- Technical
- Relative Strength Index (RSI)
- TXMD 19.09
- UMAC 58.78
- Support Level
- TXMD $1.47
- UMAC $2.45
- Resistance Level
- TXMD $1.58
- UMAC $3.53
- Average True Range (ATR)
- TXMD 0.06
- UMAC 0.48
- MACD
- TXMD -0.01
- UMAC 0.10
- Stochastic Oscillator
- TXMD 13.23
- UMAC 56.25
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About UMAC Unusual Machines Inc. Common Stock
Unusual Machines Inc is a development stage technology company.